NASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis → Move Your Money Before May 22 (From Stansberry Research) (Ad) Free UTHR Stock Alerts $235.24 -0.71 (-0.30%) (As of 02:59 PM ET) Add Compare Share Share Today's Range$234.47▼$237.5350-Day Range$214.16▼$249.5152-Week Range$204.44▼$261.54Volume172,848 shsAverage Volume435,839 shsMarket Capitalization$11.07 billionP/E Ratio11.86Dividend YieldN/APrice Target$294.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.89 Rating ScoreUpside/Downside25.4% Upside$294.25 Price TargetShort InterestHealthy9.96% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.45Based on 26 Articles This WeekInsider TradingSelling Shares$32.24 M Sold Last QuarterProj. Earnings Growth4.52%From $23.45 to $24.51 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.94 out of 5 starsMedical Sector55th out of 908 stocksPharmaceutical Preparations Industry18th out of 424 stocks 4.4 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUnited Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.96% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in United Therapeutics has recently decreased by 11.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 3.0 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 26 news articles for United Therapeutics this week, compared to 6 articles on an average week.Search Interest13 people have searched for UTHR on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $32,239,641.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 4.52% in the coming year, from $23.45 to $24.51 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 11.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 138.37.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 11.83, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 179.52.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 1.84. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesApril 26, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of StockApril 18, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $835,380.00 in StockApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 16, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,512.00 in StockApril 13, 2024 | insidertrades.comMartine A. Rothblatt Sells 13,800 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockApril 10, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 5,060 Shares of StockApril 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 15,000 SharesApril 6, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 15,000 Shares of StockApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. April 5, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) EVP Sells $1,394,220.00 in StockMarch 30, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) Director Sells 325 Shares of StockMarch 30, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 14,125 SharesApril 26, 2024 | businesswire.comCORRECTING and REPLACING PHOTO United Therapeutics Announces World's First Successful Xenothymokidney TransplantApril 26, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 Shares of StockApril 26, 2024 | marketwatch.comUnited Therapeutics Reports First Successful Xenothymokidney TransplantApril 24, 2024 | bizjournals.comLatest pig organ transplant in human marks milestone for Maryland companyApril 24, 2024 | finance.yahoo.comUnited Therapeutics Announces World’s First Successful Xenothymokidney TransplantApril 24, 2024 | businesswire.comUnited Therapeutics Announces World's First Successful Xenothymokidney TransplantApril 24, 2024 | businesswire.comUnited Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024April 24, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) Receives Average Rating of "Moderate Buy" from AnalystsApril 21, 2024 | investing.comUnited Therapeutics CEO Martine Rothblatt sells $1.7m in stockApril 21, 2024 | finance.yahoo.comUnited Therapeutics Corporation (UTHR)April 20, 2024 | americanbankingnews.comLeerink Partnrs Brokers Cut Earnings Estimates for United Therapeutics Co. (NASDAQ:UTHR)April 18, 2024 | markets.businessinsider.comUnited Therapeutics: Strategic Expansion and Competitive Edge Reinforce Outperform RatingApril 18, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) to Post Q1 2024 Earnings of $5.93 Per Share, Leerink Partnrs ForecastsApril 16, 2024 | investing.comUnited Therapeutics CEO Martine Rothblatt sells shares worth over $1.7 millionApril 16, 2024 | finance.yahoo.comUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceSee More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/21/2024Today4/26/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$294.25 High Stock Price Target$330.00 Low Stock Price Target$215.00 Potential Upside/Downside+24.7%Consensus RatingModerate Buy Rating Score (0-4)2.89 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)$19.84 Trailing P/E Ratio11.89 Forward P/E Ratio10.06 P/E GrowthN/ANet Income$984.80 million Net Margins42.31% Pretax Margin54.75% Return on Equity17.72% Return on Assets14.47% Debt Debt-to-Equity Ratio0.05 Current Ratio4.41 Quick Ratio4.28 Sales & Book Value Annual Sales$2.33 billion Price / Sales4.77 Cash Flow$21.99 per share Price / Cash Flow10.73 Book Value$127.35 per share Price / Book1.85Miscellaneous Outstanding Shares47,060,000Free Float41,177,000Market Cap$11.10 billion OptionableOptionable Beta0.52 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonSenior Vice President of Product DevelopmentMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSBioMarin PharmaceuticalNASDAQ:BMRNMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSView All CompetitorsInsiders & InstitutionsNew York State Teachers Retirement SystemBought 1,237 shares on 4/25/2024Ownership: 0.119%Zurcher Kantonalbank Zurich Cantonalbank Bought 3,948 shares on 4/25/2024Ownership: 0.053%Fjarde AP Fonden Fourth Swedish National Pension FundBought 200 shares on 4/25/2024Ownership: 0.023%Polaris Capital Management LLCSold 12,600 shares on 4/24/2024Ownership: 0.276%Assenagon Asset Management S.A.Bought 2,905 shares on 4/24/2024Ownership: 0.172%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price target for 2024? 9 brokers have issued 12-month price objectives for United Therapeutics' shares. Their UTHR share price targets range from $215.00 to $330.00. On average, they predict the company's stock price to reach $294.25 in the next year. This suggests a possible upside of 25.4% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2024? United Therapeutics' stock was trading at $219.89 at the beginning of the year. Since then, UTHR stock has increased by 6.7% and is now trading at $234.68. View the best growth stocks for 2024 here. Are investors shorting United Therapeutics? United Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 4,890,000 shares, an increase of 154.7% from the March 15th total of 1,920,000 shares. Based on an average daily trading volume, of 431,700 shares, the short-interest ratio is currently 11.3 days. Approximately 11.3% of the company's stock are sold short. View United Therapeutics' Short Interest. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our UTHR earnings forecast. How can I listen to United Therapeutics' earnings call? United Therapeutics will be holding an earnings conference call on Wednesday, May 1st at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) released its quarterly earnings results on Wednesday, February, 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating analysts' consensus estimates of $4.28 by $0.08. The biotechnology company had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a trailing twelve-month return on equity of 17.72%. United Therapeutics's revenue for the quarter was up 25.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.67 earnings per share. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Formidable Fortress ETF (KONG), Invesco Biotechnology & Genome ETF (PBE), Inspire Faithward Mid Cap Momentum ETF (GLRY) and First Trust Health Care AlphaDEX Fund (FXH). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.39%), Polaris Capital Management LLC (0.28%), Sumitomo Mitsui Trust Holdings Inc. (0.21%), Los Angeles Capital Management LLC (0.19%), Assenagon Asset Management S.A. (0.17%) and Atwood & Palmer Inc. (0.14%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UTHR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJim Cramer’s “The Biggest Drug Ever”Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.